New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 20, 2014
09:10 EDTBURL, GSK, DDD, CIDM, LEN, FSLR, XONE, BGMD, SNTA, SSYS, GES, TLYSOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Burlington Stores (BURL), up 5%... Lennar (LEN), up 2%... BG Medicine (BGMD), up 16%. ALSO HIGHER: Synta Pharmaceuticals (SNTA), up 20% after announcing positive interim results from ganetespib trial... First Solar (FSLR), up 3.5% after the company's price target was raised at Deutsche Bank, JPMorgan and RW Baird following the company issued it FY15 outlook yesterday. DOWN AFTER EARNINGS: Guess (GES), down 5%... Tilly's (TLYS), down 7%... ExOne (XONE), down 12%. Peers in 3D space down as well, with 3D Systems down 3% and Stratasys (SSYS) down 2%. ALSO LOWER: Agenus (AGEN), down 18% after announcing that GlaxoSmithKline’s (GSK) MAGRIT study, which contains Agenus’QS-21 Stimulon adjuvant, did not meet its first or second co-primary endpoint... Cinedigm Digital (CIDM), down 12% after filing to sell common stock.
News For GES;XONE;DDD;SSYS;FSLR;GSK;SNTA;LEN;BURL;BGMD;CIDM;TLYS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
February 11, 2016
08:36 EDTDDD3D Systems reports preliminary Q4 revenue about $183M, consensus $161.02M
Subscribe for More Information
05:40 EDTFSLRSolarCity downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Jon Windham downgraded SolarCity (SCTY) to Equal Weight citing the company's "weak" installation growth and guidance in Q4 and as well as investors' increasing focus on the company's near-term funding needs. Further, the U.S. Supreme Court ruling may delay action on the Clean Power Plan, Windham tells investors in a research note. He cut his price target for SolarCity shares to $20 from $49. The analyst also downgraded this morning Sunrun (RUN) to Equal Weight. Windham's top pick in the space remains First Solar (FSLR).
February 10, 2016
16:43 EDTFSLROn The Fly: Top stock stories for Wednesday
Stocks endured another roller coaster session as Fed Chair Yellen kicked off her annual pilgrimage to Capitol Hill. The averages began the day in positive territory, helped by an early rise in oil prices. The averages shot higher following a bullish oil inventory report, but soon afterward reversed and began to lose ground. The Nasdaq, which had been the strongest of the indexes throughout the day, maintained its leadership while the other indexes faltered. The Dow struggled under the weight of Disney (DIS) shares, which were lower following the company's earnings report, and gave in to the selling pressure for good late in the day, falling into the red near the close of the session. ECONOMIC EVENTS: In the U.S., Federal Reserve Chair Janet Yellen testified before the House Financial Services Committee. Tomorrow, she will present to the Senate Banking Committee. In her prepared remarks ahead of her testimony, Yellen said U.S. financial conditions have recently become "less supportive of growth," citing declines in the stock market, higher borrowing rates for riskier borrowers, and further appreciation of the dollar. Yellen also noted that foreign economic developments pose risks to domestic economic growth, noting that these growth concerns, along with strong supply conditions and high inventories, contributed to the recent fall in the prices of oil and other commodities. In a Q&A session, Yellen said she did not think recent market volatility warrants a rate cut. Separately, the Treasury announced a $55.2B budget surplus for January, much improved from the $17.5B shortfall registered in January of 2015. In Asia, Japanese stock indexes sank further, with the Topix falling another 3% and the Nikkei dropping over 2%. COMPANY NEWS: Continuing a recent trend in the media space, Time Warner (TWX) reported lower than expected quarterly revenues and saw its stock punished. The shares ended the day down 5% to $60.03, after slipping much further early in the session, despite the fact that its fourth quarter earnings topped expectations, as did its profit forecast for the new fiscal year, with the company also hiking its dividend 15% and authorizing a $5B share buyback program. Meanwhile, Disney last night reported better than expected earnings and revenue, powered by its blockbuster "Star Wars" film, but its shares fell 3.8% to $88.82 as investors continue to worry about the future of traditional media companies in the face of industry shifting trends such as cord-cutting and over-the-top video... SolarCity (SCTY) plunged 29.3% to $18.63 after reporting lower than projected installations in Q4 and giving lower than expected Q1 installation guidance. The stock's slide also weighed on its peers in the solar space, as First Solar (FSLR) fell 3% and Sunrun (RUN) dropped 15.7%. MAJOR MOVERS: Among the noteworthy gainers was Fitbit (FIT), which advanced 2.7% to $14.68 after Vanguard reported a 9.2% stake in the company and Salesforce (CRM) founder, chairman, and CEO Marc Benioff reported a 5% stake. Also higher was Neurocrine Biosciences (NBIX), which rose 4.7% to $33.70 after AbbVie (ABBV), in cooperation with the company, announced that the second Phase 3 trial of endometriosis drug Elagolix met its co-primary endpoints. Meanwhile, Akamai (AKAM) and Panera Bread (PNRA) gained 21.2% and 4.95%, respectively, after reporting quarterly results. Among the notable losers was Retrophin (RTRX), which declined 0.7% to $13.64 after Imprimis Pharmaceuticals (IMMY) said it intends to make an alternative to the company's Thiola product. Also lower were ARM Holdings (ARMH) and Demandware (DWRE), which lost 8.82% and 8.81%, respectively, after reporting quarterly results. INDEXES: The Dow fell 99.64, or 0.62%, to 15,914.74, the Nasdaq gained 14.83, or 0.35%, to 4,283.59, and the S&P 500 slipped 0.35, or 0.02%, to 1,851.86.
12:18 EDTFSLROn The Fly: Top stock stories at midday
Stocks have undergone another see-saw ride. The averages opened in positive territory, added to their gains in early trading, then saw much of their gains disappear, with the Dow now slipping below the flat line. Market watchers are intently listening as Fed Chair Janet Yellen speaks before the House Finance committee. She has maintained her mantra that the central bank will be data dependent in making its policy decisions and given little clue as to the potential pace of further rate hikes, though she did say that she does not believe the Fed will need to cut rates again. ECONOMIC EVENTS: In the U.S., Federal Reserve Chair Janet Yellen testified before the House Financial Services Committee. Tomorrow, she will present to the Senate Banking Committee. In her prepared remarks ahead of her testimony, Yellen said U.S. financial conditions have recently become "less supportive of growth," citing declines in the stock market, higher borrowing rates for riskier borrowers, and a further appreciation of the dollar. Yellen also noted that foreign economic developments pose risks to U.S. economic growth, noting that these growth concerns, along with strong supply conditions and high inventories, contributed to the recent fall in the prices of oil and other commodities. In Asia, Japanese stock indexes sank further, with the Topix falling another 3% and the Nikkei dropping over 2%. COMPANY NEWS: Continuing a recent trend in the media space, Time Warner (TWX) reported lower than expected quarterly revenues and its stock was punished. The shares were down 2% near noon, after being down much further early in the session, despite the fact that its fourth quarter earnings topped expectations, as did its profit forecast for the new fiscal year, and the company hiked its dividend 15% and approved a $5B share buyback program. Disney (DIS) last night reported better than expected earnings and revenue, powered by its blockbuster "Star Wars" film, but its shares also fell about 5% this morning as investors continue to worry about the future of traditional media companies in the face of industry shifting trends such as cord-cutting and over-the-top video... SolarCity (SCTY) plunged 20% after reporting lower than projected installations in Q4 and giving lower than expected Q1 installation guidance. A number of analysts cut their price targets on the stock but maintained their buy or equivalent ratings, though Roth Capital analyst Philip Shen downgraded SolarCity to Neutral and cut his price target for the shares to $19 from $65. SolarCity's slide weighed on its peers in the solar space as well, as First Solar (FSLR) fell 2.5% and Sunrun (RUN) dropped 12.5%. MAJOR MOVERS: Among the noteworthy gainers was Fitbit (FIT), which advanced 5% after Vanguard reported a 9.2% stake in the company and Salesforce (CRM) founder, chairman, and CEO Marc Benioff reported a 5% stake. Also higher were Akamai (AKAM), Panera (PNRA), and Sealed Air (SEE), which gained 21%, 5%, and 8%, respectively, after reporting quarterly results. Among the notable losers was Kapstone (KS), which fell 25% and was downgraded to Hold from Buy at Deutsche Bank following its Q4 earnings report. Also lower were Assurant (AIZ) and Medidata (MDSO), which were down 15% and 13%, respectively, after reporting quarterly earnings. INDEXES: Near midday, the Dow was down 9.17, or 0.06%, to 16,005.21, the Nasdaq was up 50.11, or 1.17%, to 4,318.87, and the S&P 500 was up 10.35, or 0.56%, to 1,862.56.
February 9, 2016
16:10 EDTCIDMCinedigm reports Q3 EPS (4c), consensus (4c)
Subscribe for More Information
08:40 EDTGSKVBI Vaccines announces research collaboration with GlaxoSmithKline
VBI Vaccines (VBIV) has entered into a research collaboration with GlaxoSmithKline Biologicals SA (GSK) to evaluate VBI's LPV Platform. VBI's LPV Platform is a proprietary formulation and process that enables the development of vaccines and biologics with improved stability and preserved potency. Under the terms of the research collaboration, GSK has the option to negotiate an exclusive license to VBI's LPV Platform for use in a defined field. Further terms of the collaboration were not disclosed.
February 8, 2016
08:10 EDTGSKOncoMed: FDA says PINNACLE trial should continue under supervision
Following notification of the ALPINE DSMB's findings, OncoMed (OMED) initiated interactions with tarextumab clinical investigators, partner GlaxoSmithKline (GSK), the FDA and the PINNACLE trial's DSMB chairperson to assess potential impact of these results on the overall development program, including the ongoing Phase 2 PINNACLE trial in small-cell lung cancer patients. PINNACLE trial investigators received an addendum to the informed consent form that included a description of the interim analysis from ALPINE. The FDA and the PINNACLE DSMB were provided unblinded data from both Phase 2 trials, a description of OncoMed's exploratory analysis of the ALPINE results and related trial materials for review. The independent analyses of the FDA and PINNACLE DSMB indicated that the PINNACLE trial could continue under the supervision of the PINNACLE DSMB monitoring for safety and efficacy and that appropriate safeguards are in place. OncoMed is conducting the PINNACLE Phase 1b/2 clinical trial of tarextumab for the treatment of small cell lung cancer. The randomized Phase 2 trial is comparing progression-free survival outcomes for patients treated with tarextumab administered at 15 mg/kg every three weeks in combination with etoposide and cisplatin or carboplatin versus patients who receive placebo plus chemotherapy. Additionally, PFS will be assessed using a predictive biomarker for high tumor Notch3 expression. Secondary endpoints for the Phase 2 study include overall survival, overall response rate, pharmacokinetics, safety and other biomarkers. The PINNACLE study is being conducted at about 40 sites in the U.S. and is expected to enroll approximately 130 patients. Results from the Phase 2 PINNACLE trial are anticipated in 2017.
07:03 EDTGSKBiogen joins Centre for Therapeutic Target Validation
Subscribe for More Information
06:28 EDTGSKPharma trade group rolls out ad campaign aimed at lawmakers, WSJ says
The pharmaceutical industry is launching a new ad campaign with the intention of improving its reputation with lawmakers in an effort to lobby against drug price restrictions, the Wall Street Journal reports. The industry's biggest trade group the Pharmaceutical Research and Manufacturers of America, or PhRMA, says it plans to spend several million dollars this year, and 10% more than it spent last year, on digital, radio, and print advertisements that highlight the sector's role in developing new drugs and advancing medical science, the report says. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Reference Link
February 4, 2016
07:23 EDTGSKGSK will not be pressured into early consumer unit spinoff, Reuters says
Subscribe for More Information
February 3, 2016
07:26 EDTFSLRDeutsche lists five reasons to like First Solar shares
Subscribe for More Information
07:23 EDTGSKGlaxoSmithKline confirms 2015 ordinary dividend of 80p, special dividend of 20p
Subscribe for More Information
07:23 EDTGSKGlaxoSmithKline sees double digits CER FY16 core EPS percentage growth
If FX rates held at January average levels estimated impact of +5% on 2016 Sterling core EPS growth.
07:21 EDTGSKGlaxoSmithKline reports Q4 EPS (7.3p) vs. 21.5p last year
Subscribe for More Information
February 2, 2016
10:53 EDTSSYSStratasys, MakerBot announce sales partnership program
MakerBot and Stratasys announced a sales partnership program that allows both companies to extend the cross-selling of their products and opens the door for sales partners to offer MakerBot and Stratasys 3D Printers. MakerBot is also launching a training program to familiarize Stratasys resellers and distributors with MakerBot products so they are better positioned to consult customers on the full product portfolio.
08:17 EDTGSKAdaptimmune, GSK expand strategic immunotherapy collaboration
Adaptimmune Therapeutics (ADAP) and GlaxoSmithKline (GSK) announced that the companies have expanded the terms of their strategic collaboration agreement to accelerate Adaptimmune's lead clinical cancer program, an affinity enhanced T-cell immunotherapy targeting NY-ESO-1, toward pivotal trials in synovial sarcoma. Adaptimmune and GSK announced a strategic collaboration and licensing agreement in June 2014 for up to five programs, including the lead NY-ESO TCR program. GSK has an option on the NY-ESO-1 program through clinical proof of concept and, on exercise, will assume full responsibility for the program.
07:42 EDTGSKPressure mounts on big pharma names to shrink, sharpen focus, FT says
Subscribe for More Information
06:32 EDTGSKGSK, J&J back Index Ventures' $1B biotech business spinoff, Reuters says
GlaxoSmithKline (GSK) and Johnson & Johnson (JNJ) will back a new spinoff from Index Ventures, which is spinning off its biotech portfolio into a new $1B entity, Reuters reports. The New Medicxi Ventures business will be helmed by the existing life sciences team from Index and will include all the current biotech portfolio firms, the report says. Medicxi raises $229M for a new fund in Europe with GSK and J&J each putting in 25%, Reuters reports. Reference Link
January 29, 2016
11:54 EDTGESGuess to implement program to eliminate angora fiber
The company noted, "During 2015, while developing our sustainability practices and publishing our first sustainability report, GUESS evaluated our practices related to the use of angora fibers. As a result of this process, GUESS is implementing a program to eliminate angora fiber from our future collections available in retail stores worldwide." GUESS CEO, Victor Herrero stated, "While in the past, GUESS has worked to ensure the minimal amount of angora used was ethically sourced, we feel the decision to eliminate angora moving forward is just the right thing to do."
10:05 EDTGESGuess says angora fiber 'should not be used' in production of any product
Guess?, Inc. announces that during 2015, while developing our sustainability practices and publishing its first sustainability report, it evaluated our policy related to the use of angora fiber. The company comments: "Effective immediately, angora fiber should not be used in the production of any product going forward or contained in any private label products. This pertains to promotional items as well."
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use